No value in raising HDL cholesterol: study

In the post-statin era, pharmaceutical companies are barking up the wrong tree by developing agents that increase levels of ‘good’ HDL cholesterol, a meta-analysis suggests.

None of the three classes of drug that raise HDL levels showed any benefit on clinical endpoints such as mortality, heart attacks or stroke, a new systematic review has found.

The findings showed the HDL-raising hypothesis underpinning the “next frontier” of preventative cardiovascular medicine